SAILIFE - IntraDay Trade Analysis with Live Signals
Back to ListIntraDay Trade Rating: 3.8
| Stock Code | SAILIFE | Market Cap | 22,649 Cr. | Current Price | 1,069 ₹ | High / Low | 1,090 ₹ |
| Stock P/E | 67.6 | Book Value | 109 ₹ | Dividend Yield | 0.00 % | ROCE | 14.1 % |
| ROE | 11.0 % | Face Value | 1.00 ₹ | DMA 50 | 982 ₹ | DMA 200 | 902 ₹ |
| Chg in FII Hold | -0.24 % | Chg in DII Hold | 0.13 % | PAT Qtr | 104 Cr. | PAT Prev Qtr | 83.0 Cr. |
| RSI | 64.5 | MACD | 21.6 | Volume | 14,30,564 | Avg Vol 1Wk | 7,65,708 |
| Low price | 686 ₹ | High price | 1,090 ₹ | PEG Ratio | 0.28 | Debt to equity | 0.15 |
| 52w Index | 94.9 % | Qtr Profit Var | 103 % | EPS | 15.7 ₹ | Industry PE | 30.1 |
📉 Optimal Buy Price (Today): 1,055–1,065 ₹
🎯 Profit Exit Levels: 1,085–1,095 ₹ (short scalp), 1,105–1,115 ₹ (extended momentum)
🛑 Stop-Loss: 1,040 ₹
⏳ If Already Holding: Exit near 1,085–1,095 ₹ if momentum stalls. Tighten stop-loss if price fails to sustain above 1,060 ₹. Watch RSI holding above 64 and volume expansion for continuation.
Positive
✔️ Strong quarterly PAT growth (104 Cr. vs 83 Cr., +25%)
✔️ EPS at 15.7 ₹ shows earnings consistency
✔️ PEG ratio at 0.28 indicates undervaluation relative to growth
✔️ Price above both DMA 50 (982 ₹) and DMA 200 (902 ₹) — strong uptrend
✔️ Volume (14.3L) well above weekly average (7.6L) — strong participation
Limitation
⚠️ High P/E ratio (67.6) compared to industry average (30.1)
⚠️ Dividend yield at 0.00% offers no income support
⚠️ ROE at 11.0% — moderate efficiency
Company Negative News
📉 FII holdings decreased (-0.24%)
📉 Valuation concerns due to high P/E
Company Positive News
📈 Quarterly profit doubled (+103% variation)
📈 DII holdings increased (+0.13%)
📈 52-week index gain of 94.9% shows strong investor confidence
Industry
🏭 Industry PE at 30.1 vs SAILIFE’s 67.6 — significant overvaluation compared to peers
🏭 Biopharma sector supported by strong demand and growth outlook
Conclusion
🔎 SAILIFE offers strong intraday upside with momentum supported by RSI, MACD, and high volume.
Resistance lies near 1,085–1,095 ₹, with potential extension to 1,105–1,115 ₹ if momentum sustains.
Best suited for aggressive intraday trades with strict stop-loss discipline due to valuation risks.
Would you like me to extend this into a peer benchmarking overlay against other biopharma stocks (DIVISLAB, BIOCON, LAURUSLABS) so you can see how SAILIFE stacks up intraday within its sector?